Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 29 citing articles:

Recent developments in immunotherapy for gastrointestinal tract cancers
Xiaoyi Chong, Yelizhati Madeti, Jieyuan Cai, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 21
HER2-low gastric cancer: is the subgroup targetable?
Keitaro Shimozaki, Shota Fukuoka, Akira Ooki, et al.
ESMO Open (2024) Vol. 9, Iss. 9, pp. 103679-103679
Open Access | Times Cited: 8
Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies
Jun He, Xianghua Zeng, Chunmei Wang, et al.
MedComm (2024) Vol. 5, Iss. 8
Open Access | Times Cited: 6
Antibody Drug Conjugates for Cancer Therapy: From Metallodrugs to Nature-Inspired Payloads
Giovanni Tonon, Flavio Rizzolio, Fabiano Visentin, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 16, pp. 8651-8651
Open Access | Times Cited: 5
Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions
Jiazheng Yu, Mingyang Li, Xiandong Liu, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 174, pp. 116522-116522
Open Access | Times Cited: 4
A retrospective multicenter study on the efficacy and safety of disitamab vedotin monotherapy versus combination with anti-PD-1 immunotherapy in advanced gastric cancer
Shuailei Dong, Wei Chen, Xueting Wang, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Current Landscape of Molecular Biomarkers in Gastroesophageal Tumors and Potential Strategies for Co-Expression Patterns
M. Korpan, Hannah Christina Puhr, J.M. Berger, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 340-340
Open Access
Targeting HER2 in Gastroesophageal Cancer: A New Appetite for an Old Plight
Antonella Cammarota, Rachel Woodford, Elizabeth Smyth
Drugs (2025)
Closed Access
Discussion on the mechanism of HER2 resistance in esophagogastric junction and gastric cancer in the era of immunotherapy
Yan Zhang, Wenxuan Fan, Fei Su, et al.
Human Vaccines & Immunotherapeutics (2025) Vol. 21, Iss. 1
Open Access
HER2-positive gastric cancer: from targeted therapy to CAR-T cell therapy
Qiang Shao, Junge Deng, Haoran Wu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Efficacy and safety of KN026, a bispecific anti-HER2 antibody, in combination with KN046, an anti-CTLA4/PD-L1 antibody, in patients with advanced HER2-positive nonbreast cancer: a combined analysis of a phase Ib and a phase II study
Dan Liu, Jifang Gong, Jian Li, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Evolution of HER2-low expression from primary to paired metastatic gastric cancer lesions
Wenzhuo He, Yuan-Zhong Yang, Chenxi Yin, et al.
npj Precision Oncology (2025) Vol. 9, Iss. 1
Open Access
A Case of Cervical Clear Cell Carcinoma Concurrent with Bilateral Ovarian Clear Cell Carcinoma
雅璇 张
Advances in Clinical Medicine (2025) Vol. 15, Iss. 04, pp. 2707-2714
Closed Access
RC48-ADC monotherapy or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma with HER2 low and null expression: a multicenter, real-world, retrospective study
Daining Wang, Manming Cao, Yijun Zhang, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
HER2-Targeted Therapies: Unraveling Their Role in Biliary Tract Cancers
Charalampos Theocharopoulos, Ioannis A. Ziogas, Benedetto Mungo, et al.
Critical Reviews in Oncology/Hematology (2025) Vol. 208, pp. 104655-104655
Closed Access
Clinical significance of the tumor microenvironment on immune tolerance in gastric cancer
Xiangyang He, Xin‐Yuan Guan, Yan Li
Frontiers in Immunology (2025) Vol. 16
Open Access
Prognostic value of HER2 expression in cervical adenocarcinoma: A retrospective cohort study
Qing Xu, Zhuomin Yin, Yue-Qi Li, et al.
Oncology Letters (2025) Vol. 29, Iss. 5, pp. 1-11
Open Access
Navigating the future of gastric cancer treatment: a review on the impact of antibody-drug conjugates
Qian-Qing Yin, Yanlong Zhang, Xueqing Xie, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access
Genomic and clinical characterization of HER2 exon 20 mutations in non-small cell lung cancer: insights from a multicenter study in South China
Yating Hou, Xingyang Xue, Zhuoyun Zhang, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Mechanism of action and future perspectives of ADCs in combination with immune checkpoint inhibitors for solid tumors
Yahui Lv, Xiaoran Cui, Tao Li, et al.
Clinical and Experimental Medicine (2025) Vol. 25, Iss. 1
Open Access
Antibody-drug conjugates combinations in cancer treatment
G. Pretelli, Kleida Mati, Lucia Motta, et al.
Exploration of Targeted Anti-tumor Therapy (2024) Vol. 5, Iss. 3, pp. 714-741
Open Access | Times Cited: 1
Progress and prospects of biomarker-based targeted therapy and immune checkpoint inhibitors in advanced gastric cancer
Zhu Zeng, Qing Zhu
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Antibody-drug conjugates for hepato-pancreato-biliary malignancies: “Magic bullets” to the rescue?
Charalampos Theocharopoulos, Ioannis A. Ziogas, Charalampos-Christos Douligeris, et al.
Cancer Treatment Reviews (2024) Vol. 129, pp. 102806-102806
Closed Access | Times Cited: 1
Partial response to trastuzumab deruxtecan (DS8201) following progression in HER2-amplified breast cancer with pulmonary metastases managed with disitamab vedotin (RC48): a comprehensive case report and literature review
Yanfang Lan, Jiahui Zhao, Fangrui Zhao, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
Antibody–drug conjugates in gastric cancer: from molecular landscape to clinical strategies
Jia-Lin Hao, Xinyun Li, Yu‐Tong Liu, et al.
Gastric Cancer (2024) Vol. 27, Iss. 5, pp. 887-906
Closed Access
Page 1 - Next Page

Scroll to top